# BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q2 2025 Results, Advances Toward FDA Clearance and Commercial Launch

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic agreement with standard 12-lead ECGs. HeartBeam is executing commercial readiness plans, including establishing manufacturing, logistics, and cardiologist review services, with launch expected after clearance. Additional highlights include an accepted AI algorithm abstract for HRX Live 2025, issuance of a new international patent bringing the total to 21 worldwide, and multiple industry awards. Q2 R&D expenses rose to $3.3 million from $2.8 million a year ago, while G&A fell to $1.7 million from $2.2 million. Net loss was $5.0 million, flat year-over-year. Cash, equivalents, and short-term investments totaled $5.1 million at quarter-end.

 To view the full press release, visit https://ibn.fm/qQm63

 About HeartBeam, Inc.

 HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement.

 NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-heartbeam-inc-nasdaq-beat-reports-q2-2025-results-advances-toward-fda-clearance-and-commercial-launch/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/heartbeam-advances-cardiac-care-with-fda-cleared-ecg-tech/9a1259c170bdae5018ffebc5d9df5a8f) 


Pickup - [https://faqstaq.news/news](https://faqstaq.news/news/202508/150275-heartbeam-inc-q2-2025-results-and-fda-clearance-progress-faq)

Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202508/150479-faq-on-heartbeam-inc-s-q2-2025-results-and-fda-clearance-progress)
 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1mq6e7p/heartbeam_advances_cardiac_care_with_fdacleared/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/14/sagetNDy.webp)